YBX1 and neoplasm: Overexpression of ALYREF and YBX1 was accompanied by the upregulation of immune checkpoint inhibitors (such as CD276 and PDCD1) and downregulation of immune checkpoint stimulants (such as CX3L1, ITGB2, CD40LG and SELP), which promoted evasion of immune surveillance by these tumor cells.